U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel – Reuters

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel – Reuters

The U.S. Supreme Court on Monday dashed Novartis AG’s (NOVN.S) hopes of launching a generic version of Amgen Inc’s (AMGN.O) multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company’s challenge to two patents on the drug.

Read More…

You May Also Like